Suzanna Hubele, MD
Family Medicine · Weiser, IDNPI 1477506053
Payments from drug & device makers
Across 168 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$463
- Novo Nordisk$342
- Pfizer$224
- AstraZeneca$206
- AbbVie$180
- Grifols USA, LLC$166
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,855100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 24 | $463 |
| Novo Nordisk | 21 | $342 |
| Pfizer | 15 | $224 |
| AstraZeneca | 15 | $206 |
| AbbVie(2 entities) | 11 | $180 |
| Grifols USA, LLC | 8 | $166 |
| Astellas Pharma US Inc | 9 | $123 |
| Mylan Specialty L.p. | 7 | $121 |
| Exact Sciences | 4 | $98 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $89 |
| Radius Health, Inc. | 4 | $73 |
| Sanofi-aventis U.S. LLC | 5 | $69 |
| Teva Pharmaceuticals USA, Inc. | 5 | $65 |
| Novartis | 3 | $54 |
| Bayer | 3 | $48 |
| Neurocrine Biosciences, Inc. | 2 | $42 |
| Lilly USA, LLC | 3 | $41 |
| Gilead | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Coloplast | 1 | $32 |
| Boehringer Ingelheim | 2 | $32 |
| Merck | 2 | $27 |
| Stryker | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Abbott | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $17 |
| Viatris Specialty LLC | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Lucid Diagnostics Inc. | 1 | $13 |
How this compares
$2,855 in reported general payments places this provider in the 85th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 96 | $123,231 |
| FarxigaDapagliflozin Propanediol | 80 | $98,266 |
| Avonex (4 Pack)Interferon Beta-1a | 12 | $97,601 |
| OzempicSemaglutide | 78 | $90,660 |
| JardianceEmpagliflozin | 36 | $57,210 |
| RybelsusSemaglutide | 29 | $57,026 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $38,266 |
| MounjaroTirzepatide | 26 | $34,766 |
| Nurtec OdtRimegepant Sulfate | 12 | $23,589 |
| XareltoRivaroxaban | 12 | $19,649 |
| MyrbetriqMirabegron | 22 | $19,366 |
| EntrestoSacubitril/Valsartan | 17 | $16,601 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $15,773 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $15,309 |
| JanuviaSitagliptin Phosphate | 15 | $13,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $342 | $147,687107 claims |
| PfizerEliquis, Nurtec Odt | $224 | $146,820108 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $206 | $120,741105 claims |
| Boehringer IngelheimJardiance | $32 | $57,21036 claims |
| Lilly USA, LLCMounjaro | $41 | $34,76626 claims |
| Astellas Pharma US IncMyrbetriq | $123 | $19,36622 claims |
| NovartisEntresto | $54 | $16,60117 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $69 | $15,77318 claims |
| MerckJanuvia | $27 | $13,07015 claims |
| AbbVieArmour Thyroid | $180 | $1,65014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 803 family medicine providers in Idaho.
Other family medicine in Weiser
- Mark TurnerMeridian$40.5M
- David ButukMeridian$15.2M
- Gary SoucieBlackfoot$5.8M
- Brock McConneheyBoise$4.5M
- William LaitinenMiddleton$1.1M
- Diane McConneheyBoise$681K
- Flint PackerIdaho Falls$587K
- Paul BeckettBlackfoot$344K
- Elaine DavidsonMeridian$303K
- Kenneth CongerSandpoint$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.